facebook twitter linkedin
  • images/stories/slider.png
  • images/stories/slider2.png
  • images/stories/slider3.png
  • images/stories/slider4.png

NEWS RELEASES

  • Selvita announces ten year laboratory infrastructure development plan

    Krakow, Poland – 22 September 2016 - Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has signed a preliminary agreement to purchase a land property in Krakow, Poland, where it plans to build its future drug discov…

    Read More...

  • Selvita shows 31% revenue growth in H1 2016

    Krakow, Poland - 31 August 2016 – Selvita, the largest drug discovery company in Central and Eastern Europe, has experienced a dynamic revenue growth in the first half of 2016. Net revenues from sales (excluding grants) amounted to PLN 22.7 MM, resul…

    Read More...

  • FDA has accepted Selvita's IND application for the SEL24 Phase I/II clinical trial in AML

    Kraków, Poland, 18 August 2016 – Selvita (WSE:SLV), the largest drug discovery company in Central and Eastern Europe, has received an acceptance for its IND application from the U.S. Food and Drug Administration (FDA) for SEL24, the first compound to…

    Read More...